IONIS-MAPTRx, also known as BIIB080, is an investigational antisense medicine designed to selectively inhibit production of the microtubule-associated protein tau (MAPT), or tau protein in the brain. IONIS-MAPTRx is being developed to treat people with Alzheimer’s disease (AD) and potentially other neurodegenerative disorders characterized by the deposition of abnormal tau protein within nerve cells in the brain.

About Alzheimer’s Disease (AD)

AD is the most common form of dementia in older individuals and is characterized by worsening impairments in memory and other cognitive functions, resulting in a person’s increasing inability to perform daily activities. AD usually progresses to death in five to 20 years after the onset of the disease.

Safety and efficacy have not been evaluated by any regulatory authorities for the indication described.

You are now leaving to visit